Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jiangsu Hengrui Pharmaceuticals | Hong Kong | Healthcare | Pharmaceuticals | HK$443.98B | 53.1x | 1.06 | HK$76.40 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.7% Upside | Upgrade to Pro+ | |
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$291.51B | 20x | 1.15 | HK$99.45 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.8% Upside | Upgrade to Pro+ | |
BeOne Medicines HK | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$257.63B | -184.8x | -2.77 | HK$171.40 | -6.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.6% Upside | Upgrade to Pro+ | |
Hansoh Pharmaceutical Group | Hong Kong | Healthcare | Pharmaceuticals | HK$210.01B | 32.3x | 1.08 | HK$35.48 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -14.1% Downside | Upgrade to Pro+ | |
Innovent Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$156.24B | -1,440x | -16.64 | HK$91.75 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.5% Downside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$141.28B | -133.5x | 2.03 | HK$159.80 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -27.4% Downside | Upgrade to Pro+ | |
Sino Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$130.38B | 63.9x | 1.19 | HK$7.33 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4% Downside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$122.16B | 29.3x | 21.51 | HK$29.74 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.3% Upside | Upgrade to Pro+ | |
CSPC Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$117.42B | 26.1x | -0.8 | HK$10.27 | 6.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.7% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$91.37B | -223x | -5.17 | HK$402.80 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -17.7% Downside | Upgrade to Pro+ | |
Shanghai Pharma Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$77.54B | 16.4x | 1.05 | HK$12.51 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.1% Upside | Upgrade to Pro+ | |
Shanghai Fosun Pharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$76.25B | 24.1x | 0.48 | HK$18.70 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.2% Downside | Upgrade to Pro+ | |
3SBio | Hong Kong | Healthcare | Pharmaceuticals | HK$72.33B | 32.1x | 0.87 | HK$30.24 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -14.5% Downside | Upgrade to Pro+ | |
WuXi XDC Cayman | Hong Kong | Healthcare | Pharmaceuticals | HK$69.05B | 41.6x | 0.27 | HK$56.75 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -7.7% Downside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$60.15B | 165.5x | -1.96 | HK$53 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -22.9% Downside | Upgrade to Pro+ | |
Sinopharm Group Co | Hong Kong | Healthcare | Pharmaceuticals | HK$59.07B | 7.6x | -0.37 | HK$18.93 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.2% Upside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$55.66B | 27.2x | 0.96 | HK$20.82 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.3% Downside | Upgrade to Pro+ | |
Guangzhou Baiyunshan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$47.48B | 16.1x | -0.44 | HK$17.89 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.1% Upside | Upgrade to Pro+ | |
Shanghai Junshi Biosciences | Hong Kong | Healthcare | Pharmaceuticals | HK$40.45B | -17.6x | -0.76 | HK$28.98 | 6.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -30% Downside | Upgrade to Pro+ | |
Henlius Biotech | Hong Kong | Healthcare | Pharmaceuticals | HK$39.87B | 20x | 0.84 | HK$73.20 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -12.2% Downside | Upgrade to Pro+ | |
Asymchem Laboratories Tianjin | Hong Kong | Healthcare | Pharmaceuticals | HK$39.18B | 35.3x | -0.83 | HK$91.90 | -8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -17.7% Downside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$37B | -68.2x | -0.02 | HK$16.97 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.2% Upside | Upgrade to Pro+ | |
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$36.14B | -16.5x | -2.17 | HK$60.90 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -22.2% Downside | Upgrade to Pro+ | |
Innocare | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$34.97B | -79.6x | -1.86 | HK$17.46 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -29.7% Downside | Upgrade to Pro+ | |
Livzon Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$33.22B | 17.5x | 2.12 | HK$37.24 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -8.8% Downside | Upgrade to Pro+ | |
China Resources Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$32.79B | 9x | -0.67 | HK$5.22 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.8% Upside | Upgrade to Pro+ | |
Duality Biotherapeutics | Hong Kong | Healthcare | Pharmaceuticals | HK$32.31B | -1.5x | 0.15 | HK$370.80 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -26.3% Downside | Upgrade to Pro+ | |
China Medical System | Hong Kong | Healthcare | Pharmaceuticals | HK$31.78B | 18x | -0.56 | HK$13.15 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -7.7% Downside | Upgrade to Pro+ | |
Shandong Weigao Medical Polymer | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$31.43B | 13.8x | 6.25 | HK$6.89 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.3% Downside | Upgrade to Pro+ | |
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$31.18B | -30.1x | -1.19 | HK$83.40 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -22.2% Downside | Upgrade to Pro+ | |
Simcere | Hong Kong | Healthcare | Pharmaceuticals | HK$30.88B | 38.3x | 5.14 | HK$12.40 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
United Laboratories Int | Hong Kong | Healthcare | Pharmaceuticals | HK$29.83B | 9.4x | -6.43 | HK$15.12 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.9% Upside | Upgrade to Pro+ | |
Zai Lab | Hong Kong | Healthcare | Pharmaceuticals | HK$29.58B | -14.9x | -0.56 | HK$27.30 | -10.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.1% Upside | Upgrade to Pro+ | |
XtalPi Holdings | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$29.16B | -5.4x | -0.21 | HK$7.26 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.1% Upside | Upgrade to Pro+ | |
China Grand Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$28.96B | 11.7x | 0.37 | HK$8.27 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.8% Upside | Upgrade to Pro+ | |
Ping An Healthcare Tech | Hong Kong | Healthcare | Healthcare Providers & Services | HK$27.15B | 152.6x | 2.45 | HK$12.56 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -27.2% Downside | Upgrade to Pro+ | |
MicroPort Scientific | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$25.05B | -14.8x | -0.27 | HK$13.54 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -36.2% Downside | Upgrade to Pro+ | |
Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$24.40B | 59.5x | 0.07 | HK$22.12 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -35.1% Downside | Upgrade to Pro+ | |
Shanghai MicroPort MedBot | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$22.50B | -21.5x | -0.86 | HK$21.40 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.7% Upside | Upgrade to Pro+ | |
HUTCHMED | Hong Kong | Healthcare | Pharmaceuticals | HK$22.16B | 73.6x | -1.17 | HK$23.74 | -15.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.4% Upside | Upgrade to Pro+ | |
Shanghai Conant Optics | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$21.36B | 21.8x | 1.34 | HK$44.84 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.9% Downside | Upgrade to Pro+ | |
Shenzhen Hepalink | Hong Kong | Healthcare | Pharmaceuticals | HK$20.82B | 29.4x | 0.14 | HK$6.28 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -37.6% Downside | Upgrade to Pro+ | |
Keymed Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$19.49B | -26.7x | 0.8 | HK$66.55 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -9.3% Downside | Upgrade to Pro+ | |
Cansino Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$17.37B | -39.6x | -0.84 | HK$49.26 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -13.5% Downside | Upgrade to Pro+ | |
Lepu Scientech Medical Technology | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$16.93B | -16.7x | 0.06 | HK$25.56 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -80.4% Downside | Upgrade to Pro+ | |
Luye Pharma Group | Hong Kong | Healthcare | Pharmaceuticals | HK$14.53B | 28x | -2.26 | HK$3.84 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -17.6% Downside | Upgrade to Pro+ | |
IVD Medical Holding | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$13.17B | 8.4x | -40.28 | HK$7.88 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xunfei Healthcare Technology | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$12.52B | -85.6x | -8.1 | HK$105 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.8% Upside | Upgrade to Pro+ | |
Sihuan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$12.50B | -53.6x | 0.17 | HK$1.37 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shandong Xinhua Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$12.46B | 26.3x | -1.74 | HK$7.93 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |